McKesson
在场
是其中之一......
McKesson 是一家在股票代码 MCK (US) 下上市的公司。
McKesson 在 9 个国家有直接业务。McKesson 拥有 19家子公司，其中包括 CoverMyMeds、Gehe 和 Kemofarmacija。
他们在：
高管
查看带有其 230 名主要高管的组织结构图
McKesson 搜索最多的简介
- Brian Tyler, Director, President and Chief Executive Officer
- Brad Lerman, Independent Director
- James Hinton, Director
高管在McKesson变化
- Deborah Dunsire已作为Director加入公司 (新闻发布的2024六月4号).
创建提醒
跟踪 McKesson 的高管变动
健康
McKesson 拥有 1,965 家竞争者，其中包括 Siemens Healthineers (德国)、IQVIA (美国(美洲)) 和 Nestlé Health Science (瑞士)。
Popular M&A news in 健康
- Radon Medical Imaging 已收购 Alpha Imaging (公布2024十一月20号).
- TowerBrook Capital Partners 已收购 R1 RCM (公布2024十一月19号).
- Kewaunee Scientific 已收购 Nu Aire (公布2024十一月6号).
健康 行业的其他推荐联系人
消息
McKesson 的最新新闻稿
- Ontada Collaborates with Datavant to Enable Faster Access to Market-Leading Oncology Insights I McKesson
- InspiroGene by McKesson Partners with Vertex | McKesson
- McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted Guidance | McKesson
- Ontada Collaborates with Microsoft to Transform Unstructured Oncology Data with Azure OpenAI Technology | McKesson
- InspiroGene by McKesson Publishes Cell & Gene Therapy Report | McKesson
- McKesson Launches InspiroGene | McKesson
- McKesson Corporation Announces Second Quarter Fiscal 2025 Earnings Release Date | McKesson
- VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson | McKesson
- ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson | McKesson
- RYTELO (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson | McKesson
- View more press releases Close
通过电子邮件
